Sankar D Navaneethan
Overview
Explore the profile of Sankar D Navaneethan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
254
Citations
13461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walther C, Gregg L, Navaneethan S
Am J Kidney Dis
. 2025 Mar;
PMID: 40054593
Rationale & Objective: The 2023 American Heart Association's (AHA's) Predicting Risk of Cardiovascular Disease (CVD) EVENTs (PREVENT) equations incorporate estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). We...
2.
Navaneethan S, Bansal N, Cavanaugh K, Chang A, Crowley S, Delgado C, et al.
Am J Kidney Dis
. 2024 Nov;
85(2):135-176.
PMID: 39556063
The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2024 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of chronic kidney disease (CKD)....
3.
Nicholas S, Correa-Rotter R, Desai N, Guo L, Navaneethan S, Pantalone K, et al.
J Nephrol
. 2024 Sep;
37(8):2223-2232.
PMID: 39340711
Background: Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The FINE-REAL study (NCT05348733)...
4.
Gregg L, Richardson P, Nambi V, Petersen L, Matheny M, Virani S, et al.
J Am Soc Nephrol
. 2024 Aug;
36(1):87-98.
PMID: 39186372
No abstract available.
5.
Tuttle M, Sarnak M, Navaneethan S
Curr Opin Nephrol Hypertens
. 2024 Jun;
33(5):494-502.
PMID: 38899951
Purpose Of Review: Pulmonary hypertension is a common comorbidity in patients with chronic kidney disease (CKD), but therapeutic options are limited. We discuss the epidemiology of pulmonary hypertension in patients...
6.
Lamprea-Montealegre J, Shapiro A, Bontrager N, Rifkin D, Jassal S, Gregg L, et al.
Kidney Med
. 2024 May;
6(6):100830.
PMID: 38799784
Rationale & Objective: The measurement of cystatin C has been recommended to enhance chronic kidney disease (CKD) detection and risk stratification in clinical practice. This study gathered insights into the...
7.
Natale P, Palmer S, Navaneethan S, Craig J, Strippoli G
Cochrane Database Syst Rev
. 2024 Apr;
4:CD006257.
PMID: 38682786
Background: Guidelines suggest that adults with diabetes and kidney disease receive treatment with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). This is an update of a Cochrane review published...
8.
Minhas A, Mathew R, Sperling L, Nambi V, Virani S, Navaneethan S, et al.
J Am Coll Cardiol
. 2024 Apr;
83(18):1824-1826.
PMID: 38583160
No abstract available.
9.
Walther C, Civitello A, Lamba H, Mondal N, Navaneethan S
J Am Heart Assoc
. 2024 Feb;
13(5):e031305.
PMID: 38420763
Background: Preoperative kidney dysfunction is a risk factor for right heart failure (RHF) after implantation of a left ventricular assist device (LVAD). However, characteristic kidney function trajectories before and after...
10.
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression
Holliday Jr M, Frost L, Navaneethan S
Curr Opin Nephrol Hypertens
. 2024 Feb;
33(3):331-336.
PMID: 38411162
Purpose Of Review: Diabetic kidney disease continues to increase, and several novel therapeutic agents have been shown to slow the progression of chronic kidney disease in those with diabetes. This...